Cottontail rabbit papillomavirus E6 proteins: Interaction with MAML1 and modulation of the Notch signaling pathway

Lim, JiaWen; Frecot, Desiree Isabella; Stubenrauch, Frank; Iftner, Thomas; Simon, Claudia

doi:10.1016/j.virol.2022.08.014

Cited by 1 publication

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The latter interacts with the transcriptional activation domain (TAD) of MAML2. MAML2 belongs to the MALM family (MAML1, MAML2, MAML3) and forms a DNA-binding complex with NOTCH proteins, thereby regulating transcriptional events that are specific to the NOTCH pathway, such as cell differentiation and proliferation [ 73 ]. The pathway stimulated by chimeric protein CTRC1-MAML2 is depicted in Figure 5 .…”

Section: Muco-epidermoid Carcinoma (Mec)mentioning

confidence: 99%

Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?

Perri,

Fusco,

Sabbatino

et al. 2024

Cancers

View full text Add to dashboard Cite

Salivary gland carcinomas (SGCs) are rare neoplasms, representing less than 10% of all head and neck tumors, but they are extremely heterogeneous from the histological point of view, their clinical behavior, and their genetics. The guidelines regarding their treatment include surgery in most cases, which can also play an important role in oligometastatic disease. Where surgery cannot be used, systemic therapy comes into play. Systemic therapy for many years has been represented by polychemotherapy, but recently, with the affirmation of translational research, it can also count on targeted therapy, at least in some subtypes of SGCs. Interestingly, in some SGC histotypes, predominant mutations have been identified, which in some cases behave as “driver mutations”, namely mutations capable of governing the carcinogenesis process. Targeting these driver mutations may be an effective therapeutic strategy. Nonetheless, it is not always possible to have drugs suitable for targeting driver mutations—and targeting driver mutations is not always accompanied by a clinical benefit. In this review, we will analyze the main mutations predominant in the various histotypes of SGCs.

show abstract

Section: Muco-epidermoid Carcinoma (Mec)mentioning

confidence: 99%